Skip to content
Clinical Trials – home
BelgiumBack to Belgium

Clinical trials in Ottignies-Louvain-La-Neuve – page 147

1 888 clinical trials in Ottignies-Louvain-La-Neuve, Belgium across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

Ottignies-Louvain-La-Neuve at a glance
1 888
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 888 trials in Ottignies-Louvain-La-Neuve

Open in trial search

Study of BGB-11417 for Patients with Relapsed or Refractory Mantle Cell Lymphoma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Sonrotoclax
  • Sponsor:BeOne Medicines AG

Hepatitis D

Not recruiting

Study on Bulevirtide Treatment for Patients with Chronic Hepatitis D

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bulevirtide
  • Sponsor:Gilead Sciences Inc.

Study on the Safety and Effectiveness of MK-5475 for Adults with Pulmonary Hypertension and COPD

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Frespaciguat
  • Sponsor:Merck Sharp & Dohme LLC

Obesity+1

Not recruiting

Study Comparing Tirzepatide and Semaglutide for Weight Loss in Adults with Obesity or Overweight and Related Health Issues

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Semaglutide
  • Sponsor:Eli Lilly & Co.

Study for Patients with Advanced Malignancies: Continued Treatment with Parsaclisib Alone or with Itacitinib, Ruxolitinib, Ibrutinib, or Tafasitamab

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ibrutinib
  • Sponsor:Incyte Corp.

Study on the Safety and Effectiveness of BCMACP03 for Patients with Relapsed or Refractory Multiple Myeloma

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:BCMACP03
  • Sponsor:Lakefront Biotherapeutics

Partial lipodystrophy

Not recruiting

Study on Metreleptin for Patients with Partial Lipodystrophy

Registered drug
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Metreleptin
  • Sponsor:Chiesi Farmaceutici S.p.A.

Urea cycle disorder+3

Not recruiting

Long-Term Safety Study of HepaStem for Patients with Urea Cycle Disorders, Crigler-Najjar Syndrome, and Fibroinflammatory Liver Diseases

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Hhalpc
  • Sponsor:Cellaïon SA

Cerebral haemorrhage+1

Not recruiting

Study on the Safety and Effects of Ixodes ricinus Contact Phase Inhibitor in Adults with Spontaneous Brain Bleeding

InvestigationalNo placebo
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Ixodes Ricinus Contact Phase Inhibitor
  • Sponsor:Bioxodes

Study on MK-7684A and Docetaxel for Treating Metastatic Non-Small Cell Lung Cancer in Patients After Platinum Chemotherapy and Immunotherapy

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Docetaxel
  • Sponsor:Merck Sharp & Dohme LLC

Osteoarthritis

Not recruiting

Study on the Effects of Pentosan Polysulfate Sodium for Knee Osteoarthritis Pain in Adults

Registered drug
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Paracetamol
  • Sponsor:Paradigm Biopharmaceuticals (USA) Inc.

Systemic mastocytosis

Not recruiting

Study on the Safety and Effectiveness of CGT9486 for Patients with Nonadvanced Systemic Mastocytosis

Investigational
Countries:BelgiumBelgium
  • Participants:18–64 years · 65+ years
  • Substances:Bezuclastinib
  • Sponsor:Cogent Biosciences Inc.

Other cities in Belgium

The busiest research cities in the country

All 164 cities in Belgium

Clinical research in Ottignies-Louvain-La-Neuve

What the registry says about research in the country

01 Hematology & Oncology Research

Groundbreaking clinical trials focusing on multiple myeloma treatments, specifically targeting patients with relapsed or refractory conditions. The research evaluates innovative combination therapies including talquetamab and daratumumab administration.

  • Blood Cancer Therapeutics
  • Novel Drug Combinations
  • Treatment Resistance

This comparative study aims to advance treatment options for patients who have undergone at least one prior line of therapy, potentially offering new hope for those with difficult-to-treat blood cancers.

Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease?

Tell us about your condition – we search every trial in Europe and connect you with the right site.